Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-044720
Filing Date
2024-11-12
Accepted
2024-11-12 15:34:20
Documents
61
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1439860
2 ex31-1.htm EX-31.1 18077
3 ex31-2.htm EX-31.2 17392
4 ex32.htm EX-32 8048
  Complete submission text file 0001493152-24-044720.txt   5410923

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE pvct-20240930.xsd EX-101.SCH 35591
6 XBRL CALCULATION FILE pvct-20240930_cal.xml EX-101.CAL 44773
7 XBRL DEFINITION FILE pvct-20240930_def.xml EX-101.DEF 149234
8 XBRL LABEL FILE pvct-20240930_lab.xml EX-101.LAB 295230
9 XBRL PRESENTATION FILE pvct-20240930_pre.xml EX-101.PRE 233775
63 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 814375
Mailing Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929
Business Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929 (866) 594-5999
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

EIN.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36457 | Film No.: 241447448
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)